Evidence map›Paper›PMID 22810115›Full record

ReviewCurrent psychiatry reports2012

Personalized treatment of alcohol dependence.

Henry R Kranzler, James R McKay

Registry-linked trialAbstract readReview
In one paragraph

Review in Current psychiatry reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05633186 (Sustainable Upscaling of Depression Prevention, Finding the Optimal Balance Between Investment and Benefit), which is not on this map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05633186 nacompletednot on this mapstarted 2022, after this paper: background citation

Sustainable Upscaling of Depression Prevention, Finding the Optimal Balance Between Investment and Benefit (SPRINT)

TypeinterventionalSponsorVU University of AmsterdamRan2022 to 2023Enrolled307ConditionsDepressionArmsMoodbuster Life, Mobile application, Guidance by a coach, Motivational Content
3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial
  5. Trial
  6. Subgroup Identification in Personalized Treatment of Alcohol Dependence.Alcoholism, clinical and experimental research · 2015
    Trial
  7. Trial
  8. Trial
  9. Being "SMART" About Adolescent Conduct Problems Prevention: Executing a SMART Pilot Study in a Juvenile Diversion Agency.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
    Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Constructs derived from the addiction cycle predict alcohol use disorder treatment outcomes and recovery 3 years following treatment.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Henry R KranzlerCenter for Studies of Addiction, Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104-6178, USA. kranzler@mail.med.upenn.edu
James R McKay

Funding

Research Methods CoreP01AA016821 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI LYNCH, KEVIN G · 2008 to 2012
$2.7M
Adaptive Treatment Models for the Management of Drug Use DisordersK24DA029062 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R. · 2010 to 2021
$1.6M
Novel Approaches to Alcoholism Pharmacotherapy and RiskK24AA013736 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2002 to 2012
$1.5M
NIAAA NIH HHS K24 AA013736NIAAA NIH HHS K24 AA13736NIAAA NIH HHS P01 AA016821NIDA NIH HHS K24 DA029062
6 · The paper itself

Abstract

Pharmacogenetic and adaptive treatment approaches can be used to personalize care for alcohol-dependent patients. Preliminary evidence shows that variation in the gene encoding the μ-opioid receptor moderates the response to naltrexone when used to treat alcohol dependence. Studies have also shown moderating effects of variation in the gene encoding the serotonin transporter on response to serotonergic treatment of alcohol dependence. Adaptive algorithms that modify alcohol treatment based on patients' progress have also shown promise. Initial response to outpatient treatment appears to be a particularly important in the selection of optimal continuing care interventions. In addition, stepped-care algorithms can reduce the cost and burden of treatment while maintaining good outcomes. Finally, matching treatment to specific problems present at intake or that emerge during treatment can also improve outcomes. Although all of these effects require replication and further refinement, the future of personalized care for alcohol dependence appears bright.

Indexed as

Precision MedicineAlcohol DeterrentsAlcoholismHumansNarcotic AntagonistsReceptors, OpioidSerotonin AntagonistsSerotonin Plasma Membrane Transport ProteinsAlcohol DeterrentsNarcotic AntagonistsReceptors, OpioidSerotonin AntagonistsSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID22810115
PMCPMC6431083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.